Recombinant human growth hormone (rhGH) therapy in Prader–Willi syndrome (PWS) causes increased basal metabolic rate and oxygen consumption, and hence increased ventilatory load. The case of an adolescent with PWS who experienced respiratory deterioration with an increase in rhGH and improvement with cessation of therapy is reported.
- growth hormone
- Prader-Willi syndrome
- sleep apnoea syndrome
- respiratory insufficiency
- basal metabolism
Statistics from Altmetric.com
Competing interests: none declared
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.